Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Luca Richeldi

Showing results (321-330 of 356) with videos related to

Pageof 36
Sort By:
The New England Journal of Medicine|May 20, 2014
Efficacy and safety of nintedanib in idiopathic pulmonary fibrosisLuca Richeldi, Roland M du Bois, Ganesh Raghu, et al.
Annals of Internal Medicine|May 8, 2013
Treatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel, randomized trialGanesh Raghu, Juergen Behr, Kevin K Brown, et al.
The European Respiratory Journal|May 19, 2018
Optimising experimental research in respiratory diseases: an ERS statementPhilippe Bonniaud, Aurélie Fabre, Nelly Frossard, et al.
Chest|January 15, 2021
Chest CT Diagnosis and Clinical Management of Drug-Related Pneumonitis in Patients Receiving Molecular Targeting Agents and Immune Checkpoint Inhibitors: A Position Paper From the Fleischner SocietyTakeshi Johkoh, Kyung Soo Lee, Mizuki Nishino, et al.
Cell Death and Differentiation|July 28, 2018
Paracrine signalling during ZEB1-mediated epithelial-mesenchymal transition augments local myofibroblast differentiation in lung fibrosisLiudi Yao, Franco Conforti, Charlotte Hill, et al.
Radiology|July 22, 2025
Best Practice: International Multisociety Consensus Statement for Post-COVID-19 Residual Abnormalities on Chest CT ScansSoon Ho Yoon, Jeffrey P Kanne, Kazuto Ashizawa, et al.
The Lancet. Respiratory Medicine|July 11, 2020
Interstitial lung abnormalities detected incidentally on CT: a Position Paper from the Fleischner SocietyHiroto Hatabu, Gary M Hunninghake, Luca Richeldi, et al.
Cell Reports. Medicine|August 22, 2024
Spatial transcriptomic validation of a biomimetic model of fibrosis enables re-evaluation of a therapeutic antibody targeting LOXL2Joseph A Bell, Elizabeth R Davies, Christopher J Brereton, et al.
Oncotarget|May 4, 2017
The histone deacetylase inhibitor, romidepsin, as a potential treatment for pulmonary fibrosisFranco Conforti, Elizabeth R Davies, Claire J Calderwood, et al.
European Heart Journal. Quality of Care & Clinical Outcomes|February 28, 2024
Vaccines and myocardial injury in patients hospitalized for COVID-19 infection: the CardioCOVID-Gemelli studyRocco Antonio Montone, Riccardo Rinaldi, Carlotta Masciocchi, et al.
Pageof 36

Showing results (321-330 of 356) with videos related to

Sort By:
Pageof 36
The New England Journal of Medicine|May 20, 2014
Efficacy and safety of nintedanib in idiopathic pulmonary fibrosisLuca Richeldi, Roland M du Bois, Ganesh Raghu, et al.
Annals of Internal Medicine|May 8, 2013
Treatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel, randomized trialGanesh Raghu, Juergen Behr, Kevin K Brown, et al.
The European Respiratory Journal|May 19, 2018
Optimising experimental research in respiratory diseases: an ERS statementPhilippe Bonniaud, Aurélie Fabre, Nelly Frossard, et al.
Chest|January 15, 2021
Chest CT Diagnosis and Clinical Management of Drug-Related Pneumonitis in Patients Receiving Molecular Targeting Agents and Immune Checkpoint Inhibitors: A Position Paper From the Fleischner SocietyTakeshi Johkoh, Kyung Soo Lee, Mizuki Nishino, et al.
Cell Death and Differentiation|July 28, 2018
Paracrine signalling during ZEB1-mediated epithelial-mesenchymal transition augments local myofibroblast differentiation in lung fibrosisLiudi Yao, Franco Conforti, Charlotte Hill, et al.
Radiology|July 22, 2025
Best Practice: International Multisociety Consensus Statement for Post-COVID-19 Residual Abnormalities on Chest CT ScansSoon Ho Yoon, Jeffrey P Kanne, Kazuto Ashizawa, et al.
The Lancet. Respiratory Medicine|July 11, 2020
Interstitial lung abnormalities detected incidentally on CT: a Position Paper from the Fleischner SocietyHiroto Hatabu, Gary M Hunninghake, Luca Richeldi, et al.
Cell Reports. Medicine|August 22, 2024
Spatial transcriptomic validation of a biomimetic model of fibrosis enables re-evaluation of a therapeutic antibody targeting LOXL2Joseph A Bell, Elizabeth R Davies, Christopher J Brereton, et al.
Oncotarget|May 4, 2017
The histone deacetylase inhibitor, romidepsin, as a potential treatment for pulmonary fibrosisFranco Conforti, Elizabeth R Davies, Claire J Calderwood, et al.
European Heart Journal. Quality of Care & Clinical Outcomes|February 28, 2024
Vaccines and myocardial injury in patients hospitalized for COVID-19 infection: the CardioCOVID-Gemelli studyRocco Antonio Montone, Riccardo Rinaldi, Carlotta Masciocchi, et al.
Pageof 36